Han Beth, Blanco Carlos, Einstein Emily B, Compton Wilson M
National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, USA.
Addiction. 2022 Jun;117(6):1794-1800. doi: 10.1111/add.15789. Epub 2022 Feb 15.
To examine prevalence of mental health conditions and receipt of mental health care (MHC) by illicit lysergic acid diethylamide (LSD) use status (past-year; lifetime without-past-year; never) among young adults.
Cross-sectional, annual survey data from 2015 to 2019 National Surveys on Drug Use and Health (NSDUH).
United States.
A total of 69 916 NSDUH participants ages 18 to 25.
Outcomes included past-year serious psychological distress (SPD), suicidal ideation, Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV major depressive episode (MDE), any mental illness, serious mental illness, receipt of mental health care (MHC, inpatient/outpatient or receipt of prescription medications), and number of days of being unable to work or attend normal activities because of mental health conditions.
Multivariable analyses found that compared with those who never used illicit LSD, adults with past-year illicit LSD use had greater risk of suicidal ideation (adjusted risk ratio [ARR] = 1.2, 95% CI = 1.06-1.41), SPD (ARR = 1.2, 95% CI = 1.04-1.28), MDE (ARR = 1.3, 95% CI = 1.17-1.52), and any/serious mental illness (ARRs = 1.2-1.3, 95% CI = 1.02-1.41) and reported missing more days because of mental health conditions (adjusted incidence rate ratio = 1.6, 95% CI = 1.31-1.86). Lifetime (without past-year) use showed similar, although less consistent, associations. Compared with those never using illicit LSD, adults with past-year use were less likely to receive prescription medications for MHC (ARR = 0.7, 95% CI = 0.60-0.84) and to receive overall MHC (ARR = 0.7, 95% CI= 0.64-0.84). Compared with those using in the past-year, adults with lifetime (without past-year) use were more likely to receive prescription medications for MHC (ARR = 1.2, 95% CI = 1.01-1.46) and receive overall MHC (ARR = 1.2, 95% CI = 1.03-1.45).
Young adults with past-year illicit lysergic acid diethylamide use have elevated prevalence of mental health conditions and are less likely to receive prescription medications for mental health care and overall mental health care. Regardless of past-year use status, young adults with lifetime illicit lysergic acid diethylamide use may benefit from mental illness prevention and interventions.
研究年轻成年人中，根据过去一年使用非法麦角酸二乙酰胺（LSD）的情况（过去一年使用；过去有过但过去一年未使用；从未使用），心理健康状况的患病率以及接受心理健康护理（MHC）的情况。
2015年至2019年全国药物使用和健康调查（NSDUH）的横断面年度调查数据。
美国。
总共69916名年龄在18至25岁之间的NSDUH参与者。
结果包括过去一年的严重心理困扰（SPD）、自杀意念、《精神疾病诊断与统计手册》（DSM）-IV重度抑郁发作（MDE）、任何精神疾病、严重精神疾病、接受心理健康护理（MHC，住院/门诊或接受处方药治疗）以及因心理健康状况而无法工作或参加正常活动的天数。
多变量分析发现，与从未使用过非法LSD的成年人相比，过去一年使用过非法LSD的成年人有更高的自杀意念风险（调整风险比[ARR]=1.2，95%置信区间[CI]=1.06-1.41）、SPD风险（ARR=1.2，95%CI=1.04-1.28）、MDE风险（ARR=1.3，95%CI=1.17-1.52）以及任何/严重精神疾病风险（ARRs=1.2-1.3，95%CI=1.02-1.41），并且报告因心理健康状况而缺勤的天数更多（调整发病率比=1.6，95%CI=1.31-1.86）。过去有过（过去一年未使用）使用情况的成年人也有类似的关联，尽管不太一致。与从未使用非法LSD的成年人相比，过去一年使用过的成年人接受MHC处方药治疗的可能性较小（ARR=0.7，95%CI=0.60-0.84），接受总体MHC治疗的可能性也较小（ARR=0.7，95%CI=0.64-0.84）。与过去一年使用过的成年人相比，过去有过（过去一年未使用）使用情况的成年人接受MHC处方药治疗的可能性更大（ARR=1.2，95%CI=1.01-1.46），接受总体MHC治疗的可能性也更大（ARR=1.2，95%CI=1.03-1.45）。
过去一年使用过非法麦角酸二乙酰胺的年轻成年人心理健康状况患病率较高，接受心理健康护理处方药治疗和总体心理健康护理的可能性较小。无论过去一年的使用情况如何，过去有过非法麦角酸二乙酰胺使用经历的年轻成年人可能会从精神疾病预防和干预中受益。
